Pharma Research (214450) announced on the 3rd that it has signed a strategic investment agreement with Conext to establish a mid-to-long-term partnership.
Conext is a bio venture developing protein recombinant-based biopharmaceuticals. Pharma Research recently licensed in 'CNT201,' a cellulite treatment currently under development by Conext.
CNT201, which served as the catalyst for this partnership, is a biopharmaceutical with applications ranging from cosmetic to therapeutic uses, including cellulite, Dupuytren's contracture, and Peyronie's disease. The drug recently completed Phase 1 clinical trials in the United States and is currently in Phase 2. A Pharma Research official explained, "CNT201 is differentiated in terms of safety and efficacy compared to existing treatments, showing potential to become a Best-in-Class drug."
Through this investment, Pharma Research aims to secure broad commercialization rights for CNT201 while pursuing an open innovation model to develop various biopharmaceuticals through active business partnerships based on Conext's technology capable of developing and producing diverse protein products.